ERDERA has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement N°101156595.
Views and opinions expressed are those of the author(s) only and do not necessarily reflect those of the European Union or any other granting authority, who cannot be held responsible for them.
© 2025 | ERDERA — European Rare Diseases Research Alliance
ERDERA is coordinated by Insem
ERDERA was launched in September 2024 with a remarkable budget of 380 million euros, marking a significant commitment from the European Union, Horizon Europe, and member states. Coordinated by the National Institute of Health and Medical Research (INSERM) in France, this ambitious partnership unites over 170 organizations from the public and private sectors to advance rare disease research and innovation.
In a recent interview with Science Business, ERDERA Scientific Coordinator Daria Julkowska discussed the upcoming launch of the European Rare Diseases Research Alliance (ERDERA), its mission, and its critical role in advancing rare disease research across Europe.
The European Rare Diseases Research Alliance (ERDERA) is excited to announce the call for nominations for its Multistakeholder Advisory Board (MAB). Our mission is to transform the landscape of rare disease research in Europe and improve the lives of over 30 million people living with rare diseases.
The EURORDIS Open Academy accompanies patient advocates and researchers by offering rare disease-specific comprehensive training programmes that empower them with the knowledge, skills and confidence they need to engage with different stakeholders as equal partners.
The EURORDIS Open Academy accompanies patient advocates and researchers by offering rare disease-specific comprehensive training programmes that empower them with the knowledge, skills and confidence they need to engage with different stakeholders as equal partners. READ MORE
The European Rare Diseases Research Alliance (ERDERA) kicks off this September, with an estimated budget of 380 million euros and the aim of improving the lives of 30 million rare disease patients in Europe and beyond. READ MORE
